Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial - 24/04/13
Correspondence to: Joel M. Gelfand, MD, MSCE, University of Pennsylvania School of Medicine, 2 Maloney Bldg, 3600 Spruce St, Philadelphia, PA 19104.Abstract |
Background |
There is a need for safe, inexpensive, and effective psoriasis therapies. Many anecdotal accounts of patients’ successful treatment with the alternative medicine curcumin exist.
Objective |
We sought to determine the safety and efficacy of oral curcumin in patients with psoriasis.
Methods |
We conducted a phase II, open-label, Simon’s two-stage trial of 4.5 g/d of oral curcuminoid C3 complex in patients with plaque psoriasis. End points included improvement in Physicians Global Assessment score, Psoriasis Area and Severity Index score, and safety end points throughout the study.
Results |
The intention-to-treat analysis response rate was 16.7% (95% confidence interval: 2%, 48%) and both responders achieved a Psoriasis Area and Severity Index 75 score. There were no study-related adverse events that necessitated participant withdrawal.
Limitations |
Small sample size and lack of placebo group are limitations.
Conclusion |
The response rate was low and possibly caused by a placebo effect or the natural history of psoriasis. Large placebo-controlled studies are necessary before recommending oral curcumin as a psoriasis treatment.
Le texte complet de cet article est disponible en PDF.Abbreviations used : CI, IQR, PASI, PGA, UV
Plan
| Supported by departmental funds from the Hospital of the University of Pennsylvania Department of Dermatology, National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal Skin Diseases grant K23AR051125 (Dr Gelfand), NIH/National Center for Complementary and Alternative Medicine Ruth L. Kirschstein National Research Service Award T32-AT00600 (Dr Smith), matching funds University of Pennsylvania School of Medicine (Dr Smith), NIH K30 Center for Clinical Epidemiology and Biostatistics institutional funds (Dr Smith), contributions from various pharmaceutical manufacturers to the pharmacoepidemiology training program at the Center for Clinical Epidemiology and Biostatistics of the University of Pennsylvania (Ms Kurd), the Doris Duke Charitable Foundation (Ms Kurd), and the Clinical and Translational Research Center (Research Grant UL1RR024134 from the National Center For Research Resources) at the University of Pennsylvania. Study drug was provided by the Sabinsa Corp. |
|
| Disclosure: Dr Gelfand has received grant support from Biogenidec, Amgen, Astellas, and Centocor. He has been a consultant for Genentech, Novartis, Warner-Chilcott, Amgen, Centocor, and Wyeth. Ms Kurd is supported by contributions from various pharmaceutical manufacturers to the pharmacoepidemiology training program at the Center for Clinical Epidemiology and Biostatistics of the University of Pennsylvania and the Doris Duke Charitable Foundation. Dr Badmaev is an employee of Sabinsa Corp. Dr VanVoorhees has received grant support from Amgen, Astellas, and Genentech and has been a consultant for Abbott, Amgen, Centocor, Genentech, and Warner-Chilcott. Dr Troxel has received grant support from Aetna and Centocor. Drs Smith and Seykora have no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
Vol 58 - N° 4
P. 625-631 - avril 2008 Retour au numéro
Article précédent
- Efficacy of a weekly cryotherapy regimen to treat Leishmania major cutaneous leishmaniasis
- Ibrahim M. Mosleh, Eid Geith, Lina Natsheh, Gabrielle Schönian, Nabil Abotteen, Sa’ad Kharabsheh
- Fate of manuscripts declined by the Journal of the American Academy of Dermatology
- April W. Armstrong, Shereene Z. Idriss, Alexandra B. Kimball, Jeffrey D. Bernhard
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?